Eli Lilly and (NYSE:LLY – Get Rating) announced its earnings results on Thursday. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61), Briefing.com reports. The business had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The business’s revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the business posted $1.87 earnings per share. Eli Lilly and updated its FY 2022 guidance to $7.90-$8.05 EPS.
Eli Lilly and Price Performance
Shares of NYSE:LLY traded down $4.47 during midday trading on Friday, hitting $301.32. 2,805,792 shares of the stock were exchanged, compared to its average volume of 2,923,813. The stock has a market cap of $286.30 billion, a P/E ratio of 45.01, a PEG ratio of 2.22 and a beta of 0.35. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.60. Eli Lilly and has a twelve month low of $220.20 and a twelve month high of $335.33. The company has a 50 day moving average price of $316.54 and a 200-day moving average price of $288.64.
Eli Lilly and Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Friday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is presently 58.07%.
Insider Transactions at Eli Lilly and
Institutional Trading of Eli Lilly and
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Orion Portfolio Solutions LLC grew its holdings in Eli Lilly and by 1.5% in the 1st quarter. Orion Portfolio Solutions LLC now owns 5,384 shares of the company’s stock valued at $1,542,000 after buying an additional 82 shares during the period. Worldquant Millennium Advisors LLC grew its holdings in Eli Lilly and by 587.1% in the 1st quarter. Worldquant Millennium Advisors LLC now owns 64,860 shares of the company’s stock valued at $18,574,000 after buying an additional 55,421 shares during the period. Wealthfront Advisers LLC grew its holdings in Eli Lilly and by 21.6% in the 1st quarter. Wealthfront Advisers LLC now owns 83,315 shares of the company’s stock valued at $23,859,000 after buying an additional 14,806 shares during the period. Weiss Multi Strategy Advisers LLC grew its holdings in shares of Eli Lilly and by 1.6% during the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 32,850 shares of the company’s stock worth $9,407,000 after purchasing an additional 515 shares during the period. Finally, Continuum Advisory LLC grew its holdings in shares of Eli Lilly and by 70.6% during the 1st quarter. Continuum Advisory LLC now owns 1,866 shares of the company’s stock worth $545,000 after purchasing an additional 772 shares during the period. Hedge funds and other institutional investors own 82.75% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on LLY. Mizuho raised their target price on shares of Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. StockNews.com upgraded shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 1st. SVB Leerink began coverage on shares of Eli Lilly and in a research report on Monday, May 23rd. They issued an “outperform” rating and a $341.00 price objective on the stock. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Finally, Barclays lifted their price objective on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, July 7th. Three investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Eli Lilly and presently has an average rating of “Moderate Buy” and a consensus target price of $316.06.
About Eli Lilly and
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.